AUTHORS
Carolina Velez-Mejia, MD, Esteban Toro Velez, MD2, Julie Lowman, MD3, Shejal Patel, DO4
AFFILIATIONS
1 Virginia Commonwealth University, Richmond, Virginia, United States
2 Virginia Commonwealth University, Richmond, Virginia, United States
3 Virginia Commonwealth University, Richmond, Virginia, United States
4 Virginia Commonwealth University, Richmond, Virginia, United States
ABSTRACT
Background:
Paroxysmal Nocturnal Hemoglobinuria (PNH) is an extremely rare acquired hematopoietic stem cell disorder defined by intravascular hemolysis, systemic thrombosis and bone marrow failure. While first-generation C5 inhibition with eculizumab improved the overall survival of patients with PNH, the short half-life causes significant therapeutic limitations, logistical difficulty and economic burden on patients and healthcare systems. Ravulizumab was strategically engineered to offer a sustained complement suppression with prolonged dosing intervals. Although randomized trials established that these treatments are non-inferior and health economic models have highlighted cost savings with ravulizumab, comparative real-world evidence remains limited. To our knowledge, this study represents the first large-scale evaluation directly comparing clinical outcomes between C5 inhibitors in patients with PNH.
Methods:
A retrospective cohort study using the TriNetX Global Collaborative Network was carried out. We included patients ≥ 18 years old diagnosed with PNH between March 1, 2007 (time of approval of Eculizumab) to July 31,2026 who received either eculizumab, ravulizumab or crovalimab for the treatment of PNH. Patient who had crossed-over between treatments were excluded from the analysis. Cohorts were balanced using propensity score matching for age at diagnosis, male, hemoglobin level, lactate dehydrogenase (LDH) level and presence of aplastic anemia or other bone marrow failures. Kaplan-Meier survival curves were used to assess overall survival over a 10 year follow up period.
Results:
Among 454 adult patients treated with C5 inhibitors, 280 patients were on eculizumab, 164 on ravulizumab and 10 crovalimab. The crovalimab group was excluded due to small sample size. Propensity-score matching yielded two balanced cohorts of 161 patients each to compare eculizumab vs ravulizumab.
Patients on eculizumab were more likely to require repeated transfusions than patients with ravulizumab (estimated risk of 30% vs 13%, HR 2.371, 95% CI 1.289-4.363, respectively). They were also more likely to develop breakthrough hemolysis as estimated by increase in LDH 2x upper limit of normal or hemoglobin <7g/dL (estimated risk of 50% vs 29%, HR 2.169, 95% CI 1.508-2.119). Although no statistical difference was noted, patients on eculizumab were more likely to develop a thrombotic complication even after initiation of treatment (estimated risk of 11% vs 8%, HR 1.157, 95% CI 0.517-2.589), were more prone to develop acute infections (estimated risk of 28% vs 18%, HR 1.41, 95% CI 0.821-2.422) and were more likely to have a hospital admission (estimated risk of 19% vs 12%, HR 1.28, 95% CI 0.641-2.557)
Patients on ravulizumab trended toward superior overall survival compared to those receiving eculizumab (84% vs 70%), although the difference did not achieve statistical significance [p value of 0.0662].
Due to the limited numbers of events, no data was able to be determined for increased risk for heart failure or end stage renal disease, incidence of infections due to encapsulated microorganisms, time or incidence of usage of proximal inhibitors.
Conclusions:
This data supports the preference to use ravulizumab in patients with PNH due to meaningful clinical benefits. Although overall survival did not reach statistical significance, a favorable trend was observed as well as superior disease control and reduced disease burden. Additionally, the less frequent dosing schedule of ravulizumab offers a cost-effective strategy that reduces both patient burden and healthcare utilization. These benefits are even more impactful in low and middle-income countries where resource optimization is critical. While a prospective trial would ideally validate these real-world findings, such studies remain challenging given the rarity of this disease. This data suggests that ravulizumab should be considered the preferred treatment for PNH, as it is a patient-centered therapy that delivers sustained efficacy, disease stability, and improves the healthcare resource utilization.
DISCLOSURES
Carolina Velez-Mejia, MD: No relevant conflicts of interest to declare.